EIT Pharma is a Kirkland, Washington-based clinical-stage biotechnology company developing therapies for infectious diseases with significant unmet medical needs. Its lead program, lonafarnib, is an investigational first-in-class oral candidate under FDA review for chronic hepatitis D, and its pipeline also targets acute respiratory infection. If approved, lonafarnib would be the only oral late-stage therapy option for chronic hepatitis D, offering oral dosing and room-temperature storage.
1
Round
1
Industry
5
Tags
Aug 31, 2026
Latest raise
Funding activity · 1 round
Aug 31, 2026
$35M
Series A
Led by Propel Bio Partners
Article coming soon.
Pricing
Public hubs orient you on the raise. Paid plans unlock live AI adoption signals across your market.
For individuals and small teams getting started with AI buyer intelligence.
$149
/month
Features
For outbound teams and agencies that need more coverage and faster signal cadence.
$249
/month
Features
Act on this raise
Funding is the starting point. VeilStrat shows whether capital is showing up as hiring, tools, and web activity you can sell into.
